HIA
EVOK

Harbor Investment Advisory’s Evoke Pharma EVOK Stock Holding History

Harbor Investment Advisory’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$154 – 1346
2022
Q3 		$0 Hold
7
– – ﹤0.01% 1342
2022
Q2 		$0 Buy
+7
New +$334 ﹤0.01% 1348

Other funds holding EVOK

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Harbor Investment Advisory's EVOK Position: Q4 2022 in Review

Harbor Investment Advisory sold out of Evoke Pharma (EVOK) in Q4 2022, closing a stake of 7 shares — an estimated $154 sold.

Harbor Investment Advisory first reported a position in EVOK in Q2 2022 and held it in 2 quarters. The position peaked at $0 in Q3 2022. 11 funds tracked by Wall St. Rank hold EVOK as of Q4 2022.

  • Harbor Investment Advisory reported no remaining Evoke Pharma position as of Q4 2022 after selling out during the quarter.
  • Harbor Investment Advisory sold 7 Evoke Pharma shares in Q4 2022, an estimated $154.
  • Harbor Investment Advisory first reported a position in Evoke Pharma in Q2 2022 and held it in 2 quarters.
  • Harbor Investment Advisory's Evoke Pharma position peaked at $0 in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Evoke Pharma as of Q4 2022.

Based on Harbor Investment Advisory's 13F filing for Q4 2022, filed 24 Jan 2023.